Moran Wealth Management LLC Raises Position in Catalyst Pharmaceuticals, Inc. $CPRX

Moran Wealth Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 442.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 168,961 shares of the biopharmaceutical company’s stock after purchasing an additional 137,791 shares during the quarter. Moran Wealth Management LLC owned approximately 0.14% of Catalyst Pharmaceuticals worth $4,183,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares during the period. Clearstead Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares during the period. Larson Financial Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 552.7% in the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares during the period. Advisory Services Network LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of several recent research reports. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $31.50 in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $31.45 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The stock’s fifty day moving average price is $30.93 and its two-hundred day moving average price is $26.50. The company has a market cap of $3.85 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).